Ignite Creation Date:
2024-07-17 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06472999
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-11
Brief Title:
Nephroprotective Measures in Critically Ill Patients With ModerateSevere Acute Kidney Injury
Sponsor:
Universität Münster
Organization:
Universität Münster
Study Overview
Official Title:
Implementation of Nephroprotective Measures in Critically Ill Patients With ModerateSevere Acute Kidney Injury AKI - an Observational Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
KDIGO-Bundle
Brief Summary:
This study investigates to which extent recommended nephroprotective measures are implemented in critically ill patients with moderate or severe acute kidney injury
Detailed Description:
Acute kidney injury AKI is a global problem affecting more than 10 of all hospitalized patients and up to 50 of critically ill patients with survival related not only to the severity1 but also to the duration of renal dysfunction2 Recent evidence suggests that two-thirds of patients with AKI resolve their renal dysfunction within 3-7 days whereas those in whom renal dysfunctions persist have dramatically reduced survival over the following year2 Persistence of AKI is of grave importance in that it increases an individuals risk of developing chronic kidney disease CKD which is a major cause of morbidity and mortality This link between AKI and CKD has been established over the last decade3 and specific recommendations for the management of patients with AKI have been proposed in order to potentially influence this transition4 To date there are no specific pharmacological options for preventing or treating AKI which is why new approaches and intensive efforts are urgently needed to reduce the occurrence of AKI The Kidney Disease Improving Global Outcomes KDIGO clinical practice guidelines recommend implementing a bundle of different supportive measures which in theory should be initiated in all patients with AKI in order to prevent disease progression However clinical practice and recent studies have shown that the implementation of the KDIGO bundle is still not standard clinical practice despite the fact that evidence suggest clear effectiveness in the reduction of AKI rates5-9 Poor implementation of nephroprotective measures presents a major missed opportunity to reduce AKI-related morbidity and mortality and to improve long-term outcomes To investigate the extent to which nephroprotective measures are implemented in patients with AKI can reduce the occurrence of persistent surgical AKI a multi-center prospective cohort study will be performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None